MARKET

INFI

INFI

Infinity Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.240
-0.010
-0.80%
Closed 16:00 12/06 EST
OPEN
1.250
PREV CLOSE
1.250
HIGH
1.290
LOW
1.240
VOLUME
49.08K
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
0.8200
MARKET CAP
70.72M
P/E (TTM)
-1.6087
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of INFI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

INFI News

  • Piper likes DexCom in premarket analyst action
  • Seeking Alpha - Article.11/18 13:48
  • Edited Transcript of INFI earnings conference call or presentation 30-Oct-19 8:30pm GMT
  • Thomson Reuters StreetEvents.11/09 21:04
  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.11/08 13:16
  • Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus
  • Zacks.10/31 17:45

More

Industry

Biotechnology & Medical Research
+1.28%
Pharmaceuticals & Medical Research
+0.68%

Hot Stocks

Name
Price
%Change

About INFI

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
More

Webull offers Infinity Pharmaceuticals Inc. (INFI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.